Actuate Therapeutics (ACTU) Change in Accured Expenses (2023 - 2025)
Actuate Therapeutics (ACTU) posted quarterly Change in Accured Expenses of $1.4 million for Q4 2025, up 53.38% year-over-year from $888449.0 in Q4 2024, and up 181.45% quarter-over-quarter from -$1.7 million in Q3 2025.
Actuate Therapeutics (ACTU) Change in Accured Expenses (2023 - 2025) Analysis & Trends
Actuate Therapeutics (ACTU) has reported Change in Accured Expenses for 3 consecutive years, with $1.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Accured Expenses rose 53.38% year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at -$300145.0 (down 149.13% YoY), while the FY2025 annual figure was -$300145.0, down 149.13% from the prior year.
- Change in Accured Expenses grew to $1.4 million in Q4 2025 per ACTU's latest filing, from -$1.7 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.8 million in Q2 2024 and bottomed at -$3.1 million in Q3 2024.
- Historically, Change in Accured Expenses has averaged $159487.8 across 3 years, with a median of $338202.0 in 2023.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses tumbled 1002.4% — and 2025, when it jumped 53.38%.
- Actuate Therapeutics' Change in Accured Expenses stood at $786384.0 in 2023, then climbed by 12.98% to $888449.0 in 2024, then soared by 53.38% to $1.4 million in 2025.
- Business Quant data shows ACTU's Change in Accured Expenses at $1.4 million in Q4 2025, -$1.7 million in Q3 2025, and $5062.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Actuate Therapeutics | 30.08 Mn | 30.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.36 Mn |
| Dec 31, 2025 | 1.36 Mn |
| Sep 30, 2025 | -1.67 Mn |
| Sep 30, 2025 | -1.67 Mn |
| Jun 30, 2025 | 5,062.00 |
| Jun 30, 2025 | 5,062.00 |
| Mar 31, 2025 | 5,063.00 |
| Mar 31, 2025 | 5,063.00 |
| Dec 31, 2024 | 888,449.00 |
| Dec 31, 2024 | 888,449.00 |
| Sep 30, 2024 | -3.05 Mn |
| Sep 30, 2024 | -3.05 Mn |
| Jun 30, 2024 | 2.77 Mn |
| Jun 30, 2024 | 2.77 Mn |
| Dec 31, 2023 | 786,384.00 |
| Dec 31, 2023 | 786,384.00 |
| Sep 30, 2023 | 338,202.00 |
| Sep 30, 2023 | 338,202.00 |